Attapon Cheepsattayakorn^1,2*, Ruangrong Cheepsattayakorn³ and Porntep Siriwanarangsun¹

¹Faculty of Medicine, Western University, Pathumtani Province, Thailand
²10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
³Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: December 22, 2021; Published: January 01, 2022

B.1.1.529 or Omicron variant, a variant of concern, designated by the World Health Organization (WHO) on November 26, 2021, on the suggestion of the WHO’s Technical Advisory Group on Virus Evolution (TAG-VE) [1]. Whether Omicron variant is more transmissible or causes more severe COVID-19 is not yet clear compared to other SARS-CoV-2 (COVID-19) variants, including Delta variant [1]. Several epidemiological studies are ongoing in South Africa, first country of Omicron variant identification with rising of number of SARS-CoV-2 (COVID-19)-positive persons [1]. Currently, no information on different Omicron-related symptoms is available, compared to other COVID-19 variants [1]. Increased risk of Omicron-variant reinfection could easily occur in individuals with previous COVID-19 infection [1]. Reverse-transcriptase-polymerase-chain reaction (RT-PCR) continuously is the method of Omicron variant detection [1]. A recent study in England demonstrated that the vaccine efficacy (VE) after 15 weeks of two doses of BNT162b2 (Pfizer) vaccine was around 88.0 %, whereas there was no effect against Omicron variant after two doses of ChAdOx1 (AstraZeneca) vaccine [2]. Effectiveness of current treatments currently underway [1].

References

1. World Health Organization. “Update on Omicron” (2021).
2. Andrews N., et al. “Posted on December 14, 2021. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern”. medRxiv (2021).

Citation

Citation: Attapon Cheepsattayakorn., et al. “COVID-19 Vaccine Efficacy on Omicron Variant”. Acta Scientific Microbiology 5.2 (2022): 01.

Copyright

Copyright: © 2022 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.